Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019

Antimicrobial susceptibility of clinical isolates collected from sites in central Europe in 2019 was tested by CLSI broth microdilution method and EUCAST breakpoints. Most active were amikacin, ceftazidime-avibactam and colistin; respectively, susceptibility rates among P. aeruginosa (n = 701) were...

Descripción completa

Detalles Bibliográficos
Autores principales: Adámková, V, Mareković, I, Szabó, J, Pojnar, L, Billová, S, Horvat Herceg, S, Kuraieva, A, Możejko-Pastewka, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135846/
https://www.ncbi.nlm.nih.gov/pubmed/35596097
http://dx.doi.org/10.1007/s10096-022-04452-1
_version_ 1784714052694441984
author Adámková, V
Mareković, I
Szabó, J
Pojnar, L
Billová, S
Horvat Herceg, S
Kuraieva, A
Możejko-Pastewka, B
author_facet Adámková, V
Mareković, I
Szabó, J
Pojnar, L
Billová, S
Horvat Herceg, S
Kuraieva, A
Możejko-Pastewka, B
author_sort Adámková, V
collection PubMed
description Antimicrobial susceptibility of clinical isolates collected from sites in central Europe in 2019 was tested by CLSI broth microdilution method and EUCAST breakpoints. Most active were amikacin, ceftazidime-avibactam and colistin; respectively, susceptibility rates among P. aeruginosa (n = 701) were 89.2%, 92.2% and 99.9%; difficult-to-treat (DTR) isolates, 62.5%, 37.5% and 100%; multidrug-resistant (MDR) isolates, 68.3%, 72.9% and 99.5%; meropenem-resistant (MEM-R), metallo-β-lactamase-negative (MBL-negative) isolates, 72.8%, 78.6% and 100%. Among Enterobacterales (n = 1639), susceptibility to ceftazidime-avibactam, colistin and tigecycline was ≥ 97.9%; MDR Enterobacterales, 96.8%, 94.4% and 100%, respectively; DTR isolates, ≥ 76.2% to ceftazidime-avibactam and colistin; MEM-R, MBL-negative isolates, ≥ 90.0% to ceftazidime-avibactam and colistin.
format Online
Article
Text
id pubmed-9135846
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-91358462022-05-28 Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019 Adámková, V Mareković, I Szabó, J Pojnar, L Billová, S Horvat Herceg, S Kuraieva, A Możejko-Pastewka, B Eur J Clin Microbiol Infect Dis Brief Report Antimicrobial susceptibility of clinical isolates collected from sites in central Europe in 2019 was tested by CLSI broth microdilution method and EUCAST breakpoints. Most active were amikacin, ceftazidime-avibactam and colistin; respectively, susceptibility rates among P. aeruginosa (n = 701) were 89.2%, 92.2% and 99.9%; difficult-to-treat (DTR) isolates, 62.5%, 37.5% and 100%; multidrug-resistant (MDR) isolates, 68.3%, 72.9% and 99.5%; meropenem-resistant (MEM-R), metallo-β-lactamase-negative (MBL-negative) isolates, 72.8%, 78.6% and 100%. Among Enterobacterales (n = 1639), susceptibility to ceftazidime-avibactam, colistin and tigecycline was ≥ 97.9%; MDR Enterobacterales, 96.8%, 94.4% and 100%, respectively; DTR isolates, ≥ 76.2% to ceftazidime-avibactam and colistin; MEM-R, MBL-negative isolates, ≥ 90.0% to ceftazidime-avibactam and colistin. Springer Berlin Heidelberg 2022-05-20 2022 /pmc/articles/PMC9135846/ /pubmed/35596097 http://dx.doi.org/10.1007/s10096-022-04452-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Report
Adámková, V
Mareković, I
Szabó, J
Pojnar, L
Billová, S
Horvat Herceg, S
Kuraieva, A
Możejko-Pastewka, B
Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019
title Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019
title_full Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019
title_fullStr Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019
title_full_unstemmed Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019
title_short Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019
title_sort antimicrobial activity of ceftazidime-avibactam and comparators against pseudomonas aeruginosa and enterobacterales collected in croatia, czech republic, hungary, poland, latvia and lithuania: atlas surveillance program, 2019
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135846/
https://www.ncbi.nlm.nih.gov/pubmed/35596097
http://dx.doi.org/10.1007/s10096-022-04452-1
work_keys_str_mv AT adamkovav antimicrobialactivityofceftazidimeavibactamandcomparatorsagainstpseudomonasaeruginosaandenterobacteralescollectedincroatiaczechrepublichungarypolandlatviaandlithuaniaatlassurveillanceprogram2019
AT marekovici antimicrobialactivityofceftazidimeavibactamandcomparatorsagainstpseudomonasaeruginosaandenterobacteralescollectedincroatiaczechrepublichungarypolandlatviaandlithuaniaatlassurveillanceprogram2019
AT szaboj antimicrobialactivityofceftazidimeavibactamandcomparatorsagainstpseudomonasaeruginosaandenterobacteralescollectedincroatiaczechrepublichungarypolandlatviaandlithuaniaatlassurveillanceprogram2019
AT pojnarl antimicrobialactivityofceftazidimeavibactamandcomparatorsagainstpseudomonasaeruginosaandenterobacteralescollectedincroatiaczechrepublichungarypolandlatviaandlithuaniaatlassurveillanceprogram2019
AT billovas antimicrobialactivityofceftazidimeavibactamandcomparatorsagainstpseudomonasaeruginosaandenterobacteralescollectedincroatiaczechrepublichungarypolandlatviaandlithuaniaatlassurveillanceprogram2019
AT horvathercegs antimicrobialactivityofceftazidimeavibactamandcomparatorsagainstpseudomonasaeruginosaandenterobacteralescollectedincroatiaczechrepublichungarypolandlatviaandlithuaniaatlassurveillanceprogram2019
AT kuraievaa antimicrobialactivityofceftazidimeavibactamandcomparatorsagainstpseudomonasaeruginosaandenterobacteralescollectedincroatiaczechrepublichungarypolandlatviaandlithuaniaatlassurveillanceprogram2019
AT mozejkopastewkab antimicrobialactivityofceftazidimeavibactamandcomparatorsagainstpseudomonasaeruginosaandenterobacteralescollectedincroatiaczechrepublichungarypolandlatviaandlithuaniaatlassurveillanceprogram2019

Ejemplares similares